SLNOAnother courtroom cameo
Soleno Therapeutics is back in the spotlight for the kind of reason companies hate: a securities fraud class action. According to Bernstein Liebhard LLP, the lawsuit was filed on behalf of investors who bought Soleno common stock between March 26, 2025 and August 4, 2025.
What’s the beef?
The complaint says defendants allegedly made misrepresentations about the company’s Phase 3 clinical trial program for DCCR. In plain English: investors are arguing the story they were sold didn’t match the reality on the ground.
Why you should care
Lawsuits like this don’t always change the underlying science, but they can absolutely change the mood music. For a biotech, that means extra legal costs, more uncertainty, and another thing for traders to obsess over while the stock tries to find its footing.
The investor takeaway
This is more about risk overhang than instant business damage, but it still matters. If the allegations gain traction, Soleno could face reputation pain and a longer road to rebuilding investor trust.
Big picture: biotech investing already has enough drama without adding a class action plot twist, but here we are.